Dutch conglomerate Philips has partnered with Flex and Jabil to accelerate the production of its hospital ventilators and bolster global supply.
Hospital ventilators are required to treat Covid-19 patients suffering from respiratory insufficiency.
Philips’ critical care ventilators are said come with life support and invasive ventilation capabilities, battery back-up, redundant safety controls and compatibility for patient monitors and nurse alarms.
In addition, the company’s software algorithms could adapt therapy based on lung compliance and airway resistance, catering to individual patient needs.
Philips is increasing the production of these ventilators, which comprise more than 650 components, from 500 units per week in January 2020 to 4,000 units per week by the third quarter of this year.
Flex and Jabil are expected to support the project via medical device technologies expertise, global footprint, as well as materials and component suppliers network.
Royal Philips chief operations officer Sophie Bechu said: “Following the initial hospital ventilator production increase in late January, we decided to aggressively accelerate our hospital ventilator production as the epicenter of the COVID-19 pandemic began to shift from China to the west.
“Our trusted partners Flex and Jabil will provide additional assembly lines, and equally important will help manage and support the supply of the components.“
Philips Trilogy hospital ventilator will be produced at assembly lines in the company’s manufacturing site in western Pennsylvania, US and at Flex.
The assembly lines at Philips’ site in California, US and Jabil will work to produce the Philips Respironics V60 hospital ventilator.
Furthermore, the company launched a new emergency use ventilator, called Philips Respironics E30, to offer invasive and non-invasion oxygen support for Covid-19 patients.
Philips will start production immediately and aims to generate 15,000 units per week this month.